Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma

US Patent 11124577 · Granted Sep 21, 2021

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibodies against CEACAM5 and CD32025
Bispecific antibodies against CD3EPSILON and ROR12024
Bispecific antibodies against CD3EPSILON and ROR12024
Bispecific antibodies against CEACAM5 and CD472023
Method for the selection of antibodies against BCMA2020
Method for the selection of antibodies against BCMA2020
Monoclonal antibodies against BCMA2020
Monoclonal antibodies against BCMA2020
Bispecific antibodies against CD3ϵ and BCMA2019
Bispecific antibodies against CD3ϵ and BCMA2019
Bispecific antibodies against CD3 and BCMA2018
Bispecific antibodies against CD3 and BCMA2018